Peter Morris

Medicine & Life Sciences

1. Child 100%
2. Otitis Media 92%
3. Bronchiectasis 66%
4. Randomized Controlled Trials 60%
5. Conjugate Vaccines 47%
6. Northern Territory 43%
7. Suppurative Otitis Media 42%
8. Azithromycin 38%
9. Haemophilus influenzae 35%
10. Streptococcus pneumoniae 34%
11. Cough 33%
12. Pneumococcal Vaccines 32%
13. Anti-Bacterial Agents 32%
14. Haemophilus influenzae glpQ protein 26%
15. Ear 24%
16. Bronchiolitis 24%
17. Serogroup 22%
18. Placebos 20%
19. 13-valent pneumococcal vaccine 20%
20. Vaccines 18%
21. Middle Ear 18%
22. Lung Diseases 18%
23. Otitis Media with Effusion 17%
24. Respiratory Tract Infections 16%
25. Appointments and Schedules 16%
26. Health 15%
27. Nasopharynx 14%
28. New Zealand 13%
29. Tympanic Membrane Perforation 13%
30. Nose 13%
31. Vaccination 13%
32. Hearing Loss 13%
33. Amoxicillin 12%
34. Population 12%
35. PHiD-CV vaccine 12%
36. Pneumonia 12%
37. Moraxella catarrhalis 11%
38. Ear Diseases 11%
39. Local Anti-Infective Agents 10%
40. Systematic Reviews 10%
41. Fibrosis 10%
42. Population Groups 9%
43. Microbiology 9%
44. Pediatrics 9%
45. Hospitalized Child 9%
46. Vulnerable Populations 9%
47. Therapeutics 9%
48. Confidence Intervals 8%
49. Bacteria 8%
50. Minority Groups 8%